Prediction of Lymphatic Spreading in Prostatic Cancer by Prostate-Specific Antigen and Gleason's Score

1994 ◽  
Vol 26 (3) ◽  
pp. 202-206 ◽  
Author(s):  
Tony T. Wu ◽  
Kuang-Kuo Chen ◽  
Jong-Khing Huang ◽  
Ying-Huei Lee ◽  
Ming-Tsun Chen ◽  
...  
Keyword(s):  
Prostate Specific Antigen ◽  
Prostatic Cancer ◽  
Specific Antigen ◽  
Lymphatic Spreading

Clinical Usefulness of Prostate-Specific Antigen and Prostatic Acid Phosphatase in Patients with Prostatic Cancer

Tumor Biology ◽  
1990 ◽  
Vol 11 (6) ◽  
pp. 289-294 ◽  
Author(s):  
X. Filella ◽  
R. Molina ◽  
J. Jo ◽  
B. Umbert ◽  
J.L. Bedini ◽  
...  
Keyword(s):  
Acid Phosphatase ◽  
Prostate Specific Antigen ◽  
Prostatic Cancer ◽  
Specific Antigen ◽  
Prostatic Acid Phosphatase ◽  
Clinical Usefulness

Trimetrexate in prostatic cancer: preliminary observations on the use of prostate-specific antigen and acid phosphatase as a marker in measurable hormone-refractory disease.

1990 ◽  
Vol 8 (11) ◽  
pp. 1830-1838 ◽  
Author(s):  
H I Scher ◽  
T Curley ◽  
N Geller ◽  
C Engstrom ◽  
D D Dershaw ◽  
...  
Keyword(s):  
Acid Phosphatase ◽  
Prostate Specific Antigen ◽  
Biochemical Markers ◽  
Prostatic Cancer ◽  
Specific Antigen ◽  
Decision Rules ◽  
Refractory Disease ◽  
Disease Response ◽  
Analysis Technique ◽  
Hormone Refractory

Thirty-one patients with bidimensionally measurable hormone-refractory prostatic cancer received trimetrexate (TMTX). Serial values of prostate-specific antigen (PSA) and acid phosphatase (SAP) were correlated with response. Five patients (17%; 95% confidence interval, 3% to 30%) achieved a partial remission for a median of 3 months (range, 3 to 7.5 months). Marker levels showed large variations with no discernible patterns. Serial PSA and SAP in 19 patients with abnormal baseline values showed a correlation with measurable disease response in only 68% (13 of 19) and 47% (nine of 19) of patients, respectively. Values were then smoothed using an exploratory data analysis technique of running medians and averages. Trends in marker changes were much more apparent. Several "decision rules" were evaluated for use of markers as indices of disease progression. A 50% increase from the patient's minimum value in either PSA or SAP on two successive determinations correlated with progression in 90% of cases in this trial. TMTX has modest activity in prostatic cancer, and further trials are not warranted. Biochemical markers do not uniformly reflect disease activity in hormone-refractory disease, and changes in biochemical markers must be interpreted cautiously when used as the sole end point to assess efficacy in clinical trials.

Diagnostic Accuracy of Percent Free Prostate-Specific Antigen in Prostatic Pathology and Its Usefulness in Monitoring Prostatic Cancer Patients

2001 ◽  
Vol 67 (4) ◽  
pp. 272-282 ◽  
Author(s):  
Daniele Minardi ◽  
Andrea Benedetto Galosi ◽  
Alberto Recchioni ◽  
Lisy Giammarco ◽  
Mario Polito ◽  
...  
Keyword(s):  
Diagnostic Accuracy ◽  
Cancer Patients ◽  
Prostate Specific Antigen ◽  
Prostatic Cancer ◽  
Specific Antigen

Percentage of free serum prostate-specific antigen: A new tool in the early diagnosis of prostatic cancer

1996 ◽  
Vol 32 (12) ◽  
pp. 2088-2093 ◽  
Author(s):  
M.-E. Toubert ◽  
J. Guillet ◽  
M. Chiron ◽  
P. Meria ◽  
C. Role ◽  
...  
Keyword(s):  
Early Diagnosis ◽  
Prostate Specific Antigen ◽  
Prostatic Cancer ◽  
Specific Antigen ◽  
Serum Prostate Specific Antigen ◽  
Antigen A ◽  
Free Serum

scholarly journals Perineural invasion, Gleason score and prostate specific antigen; is there any association?

2019 ◽  
Vol 8 (4) ◽  
pp. 37-37
Author(s):  
Mohammad Yazdani ◽  
Ali Karami ◽  
Emadeddin Yazdani-Kachouei ◽  
Farhad Tadayon
Keyword(s):  
Prostate Specific Antigen ◽  
Gleason Score ◽  
Prostatic Cancer ◽  
Perineural Invasion ◽  
Specific Antigen ◽  
Cross Sectional Study ◽  
Common Finding ◽  
Sectional Study ◽  
Cross Sectional ◽  
Prostate Biopsies

Introduction: Prostatic cancer is one of the most common malignancies among males. Perineural invasion (PNI) is a common finding of prostate cancer associated with more aggressive malignancies. Objectives: The current study was conducted to assess the association of PNI with serum prostate specific antigen (PSA) and Gleason score. Patients and Methods: This analytical cross-sectional study conducted on 354 known cases of prostatic cancer (2015 until 2017). Patients’ last PSA and Gleason score wit h presence/lack of PNI in their prostate biopsies were recorded. The association of PNI with PSA and Gleason score was assessed. Results: Serum level of PSA and Gleason core were significantly higher in patients with PNI (P< 0.001 for both). Gleason score was independently a predictor of PNI (odds ratio [OR]: 3.05, 95% CI:2.32- 4.001; P=0.001). Serum PSA level of 17 ng/mL had specificity of 90.3% and sensitivity of 42.7% for prediction of PNI. Conclusion: In this study we found, Gleason score is independently a prognostic factor of PNI among cases undergone prostate biopsy. In addition, serum PSA level of 17 ng/mL was 90.3% specific and 42.7% sensitive for PNI occurrence. However, our findings require further evaluations by larger studies.

Sign in / Sign up

Export Citation Format

Share Document